CD274 and non-small cell lung carcinoma: In late stage NSCLC, programmed death ligand 1 (PD-L1) expression by immunohistochemistry (IHC) is used in the clinical setting as a predictive biomarker as it may predict response to ICIs that target the programmed death receptor-1 (PD-1)/PD-L1 immune checkpoint pathway [4].